research Pathogenesis of paradoxical alopecia areata during dupilumab therapy: What is known and unknown
Dupilumab can both improve and worsen alopecia areata, with higher IgE levels linked to better outcomes.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch Emerging Topical and Systemic JAK Inhibitors in Dermatology
JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
research Dupilumab and alopecia: A Janus effect
Dupilumab can both heal and cause hair loss.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research 735 - A case series of dupilumab for vitiligo and alopecia areata in the setting of AD
Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.
research Inflammatory loops in the epithelial–immune microenvironment of the skin and skin appendages in chronic inflammatory diseases
Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.
research Alopecia Areata Associated with Dupilumab: National Database Study
Dupilumab users have a higher risk of developing alopecia areata.
research LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research From Bald to Bold: Reversal of Alopecia Totalis in an Adolescent Using Dupilumab Monotherapy
Dupilumab helped a 13-year-old regrow hair after alopecia totalis.
research Alopecia Areata Associated with Dupilumab: A Case Report and Literature Review
Dupilumab may cause hair loss, so patients should be monitored.
research The use of dupilumab for the treatment of alopecia areata
Dupilumab may help treat alopecia areata, but more research is needed.
research BH02 (P100) Critically appraised topic: is dupilumab a cause or a treatment for alopecia areata? A case series and literature review to guide discussions in clinical practice
Dupilumab can both trigger and treat alopecia areata, often leading to hair regrowth.
research P100 Critically appraised topic: is dupilumab a cause or a treatment for alopecia areata? A case series and literature review to guide discussions in clinical practice
Dupilumab can both cause and treat alopecia areata, with many patients experiencing hair regrowth.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research 104 Willingness-to-pay of patients with chronic skin diseases: A pilot study
Vitiligo patients are willing to pay the most for treatment, regardless of disease severity.
research Clinicoepidemiological profile, precipitating factors and severity indicators in alopecia areata in Manipur
Psychological stress is a major factor in the onset and severity of alopecia areata, with atopic individuals being more prone to develop it.
research Hair and nail adverse events during treatment with target therapies for metastatic melanoma
People with certain allergic conditions or higher white blood cell counts have more severe hair loss, and treating hair and nail side effects early in melanoma therapy can improve quality of life.
research Clinical Characteristics and Prognostic Factors in Early-Onset Alopecia Totalis and Alopecia Universalis
Early-onset alopecia, especially with a family history, leads to worse outcomes and more related health issues.
research Management and Genetics of Alopecia Areata within the USA: A Cross-Sectional Study of All of Us
Healthcare access for alopecia areata in the USA is unequal among ethnic groups.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
AA patients with comorbid conditions face more severe hair loss and need specific treatments.
research The immunopathogenesis of Alopecia Areata
Alopecia areata is an autoimmune disease causing hair loss, and targeting macrophages may help treat it.
research Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack
Hair follicles prevent NK cell attacks to avoid hair loss.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Management of hair loss diseases
New treatments for hair loss show promise, but more development is needed, especially for tough cases.
research The Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review
Antihistamines may help with hair regrowth in alopecia areata, but dupilumab's effects are mixed.
research Pigmented contact dermatitis due to therapeutic sensitizer as complication of contact immunotherapy in alopecia areata
Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.
research Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.